Beksinska Mags, Cartwright Alice F, Smit Jennifer, Kasaro Margaret, Tang Jennifer H, Fawzy Maria, Maphumulo Virginia, Chinyama Manze, Chabu Esther, Callahan Rebecca
MRU (MatCH Research Unit), Department of Obstetrics & Gynaecology, Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa.
FHI 360, Durham, NC, United States.
Contracept X. 2023 Jan 16;5:100089. doi: 10.1016/j.conx.2023.100089. eCollection 2023.
To assess differences in HIV testing at 6-months intervals over 24 months among intramuscular depot medroxyprogesterone acetate (DMPA-IM) injectable, levonorgestrel implant, or copper intrauterine devices (IUD) users in KwaZulu-Natal, South Africa, and Lusaka, Zambia. Testing at recommended intervals has not been previously assessed in long-acting reversible contraceptive (LARC) users (implant and IUD users) compared to those using effective but shorter-acting methods (such as DMPA-IM) in sub-Saharan Africa.
As part of the longitudinal contraceptive use beyond ECHO (CUBE) study, we measured HIV testing over 24 months. Participants were considered continuous users of DMPA-IM, levonorgestrel implant, or copper IUD if they used the same method across all months of their study participation, or not continuous users of their baseline CUBE method if they switched or discontinued their method. We used multivariable logistic regression models with generalized estimating equations and robust standard errors, stratified by country, to assess differences in HIV testing.
Among the 498 participants, HIV testing rates were higher in Zambia for all methods compared to South Africa. In bivariate analyses, continuous implant or IUD users (the LARC users) were significantly less likely to report having received HIV testing at the 6-months and 24-months surveys, compared to continuous DMPA-IM users. In adjusted longitudinal models, continuous IUD users (adjusted odds ratio: 0.42, 95% CI: 0.24, 0.74), continuous implant users (adjusted odds ratio: 0.23, 95% CI: 0.12, 0.42) in South Africa had significantly lower odds of HIV testing compared to continuous DMPA-IM users. There were no significant differences in Zambia in the adjusted models.
LARC use may reduce opportunities for HIV testing and users should be counseled on regular HIV testing and the option of HIV self-testing.
Due to infrequent clinical contacts which may lead to lower rates of HIV testing at recommended intervals, LARC users should be provided opportunities to test for HIV at home or when seeking other health services.
评估在南非夸祖鲁 - 纳塔尔省和赞比亚卢萨卡,接受醋酸甲羟孕酮长效注射剂(DMPA - IM)、左炔诺孕酮宫内节育器或铜宫内节育器(IUD)的使用者在24个月内每6个月进行一次HIV检测的差异。与撒哈拉以南非洲地区使用有效但作用时间较短方法(如DMPA - IM)的使用者相比,长效可逆避孕法(LARC,即宫内节育器和植入剂使用者)按推荐间隔进行检测的情况此前尚未得到评估。
作为超越ECHO的长效避孕使用(CUBE)纵向研究的一部分,我们在24个月内对HIV检测情况进行了测量。如果参与者在整个研究参与期间都使用相同的方法,则被视为DMPA - IM、左炔诺孕酮宫内节育器或铜宫内节育器的持续使用者;如果他们更换或停用了基线CUBE方法,则被视为其基线CUBE方法的非持续使用者。我们使用带有广义估计方程和稳健标准误的多变量逻辑回归模型,按国家分层,以评估HIV检测的差异。
在498名参与者中,赞比亚所有方法的HIV检测率均高于南非。在双变量分析中,与持续使用DMPA - IM的使用者相比,持续使用宫内节育器或植入剂的使用者(即LARC使用者)在6个月和24个月调查时报告接受HIV检测的可能性显著更低。在调整后的纵向模型中,南非持续使用宫内节育器的使用者(调整后的优势比:0.42,95%置信区间:0.24,0.74)、持续使用植入剂的使用者(调整后的优势比:0.23,95%置信区间:0.1 / 0.42)与持续使用DMPA - IM的使用者相比,HIV检测的几率显著更低。在赞比亚,调整后的模型中没有显著差异。
使用LARC可能会减少HIV检测的机会,应对使用者进行定期HIV检测及HIV自我检测选项方面的咨询。
由于临床接触不频繁可能导致按推荐间隔进行HIV检测的比率较低,应向LARC使用者提供在家中或寻求其他医疗服务时进行HIV检测的机会。